A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Clinical trial NCT06001086 · RECRUITING
Trial details
- NCT number
- NCT06001086
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2026-08-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.